Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.
Contineum Therapeutics has commenced patient dosing in a Phase 1b clinical trial evaluating PIPE-791, an LPA1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.